Edwards Lifesciences upgraded to Buy on pipeline readouts at BofA/Merrill

BofA/Merrill upgraded Edwards Lifesciences (EW) to Buy from Neutral and raised its price target to $190 from $180. Analyst Bob Hopkins expects Edwards’ multiple to move higher as investors digest upcoming pipeline readouts for Low Risk Aortic and Mitral Repair over the next five months. Further, the US Pascal trial requires only a six month followup, indicating that approval could come earlier than expected, the analyst wrote in a note to investors.
https://thefly.com/landingPageNews.php?id=2850859